1410P - Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Sarcoma
Presenter Attila Kollar
Citation Annals of Oncology (2016) 27 (6): 483-492. 10.1093/annonc/mdw388
Authors A. Kollar1, R.L. Jones2, S. Stacchiotti3, H. Gelderblom4, M. Guida5, P. Boccone6, N. Steeghs7, A. Safwat8, D. Katz9, F. Duffaud10, S. Sleijfer11, W. van der Graaf12, N. Touati13, S. Litière14, S. Marreaud13, A. Gronchi15, B. Kasper16
  • 1Medizinische Onkologie, Inselspital - Universitätsspital Bern, 3010 - Bern/CH
  • 2Medical Oncology, Royal Marsden Hospital, SW3 6JJ - London/GB
  • 3Department Of Cancer Medicine, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano/IT
  • 4Clinical Oncology, Leiden University Medical Center (LUMC), 2300 - Leiden/NL
  • 5Medical Oncology, Istituto Tumori Giovanni Paolo II, 70124 - Bari/IT
  • 6Medical Oncology, Candiolo Cancer Institute, Torino/IT
  • 7Clinical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 8Department Of Oncology, Aarhus University Hospital, Aarhus C/DK
  • 9Oncology, Hadassah Ein Kerem, Jerusalem/IL
  • 10Medical Oncology, Centre Hospitalier Universitaire Timone, 13385 - Marseille/FR
  • 11Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, 3075 EA - Rotterdam/NL
  • 12Medical Oncology, Institute of Cancer Research and the Royal Marsden NHS Fondation Trust, SW3 6JJ - London/GB
  • 13Eortc Headquarters, European Organisation for research and treatment of Cancer (EORTC), Brussels/BE
  • 14Eortc Headquarters, European Organisation for Research and Treatment of Cancer (EORTC AISBL), 1200 - Brussels/BE
  • 15Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 16Interdisziplinäres Tumorzentrum Mannheim (itm), Universitätsklinikum Mannheim, 68167 - Mannheim/DE

Abstract

Background

Pazopanib is a multitargeted tyrosine kinase inhibitor approved for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma who have previously received standard chemotherapy including anthracyclines or were unfit for anthracyclines. Data on its efficacy in vascular sarcomas are limited. The main objective of this study was to investigate the activity of pazopanib in vascular sarcomas.

Methods

Clinical data of patients with advanced vascular sarcomas, including angiosarcoma (AS), hemangioendothelioma (HE) and intimal sarcoma (IS) treated with pazopanib in a real-life setting were retrospectively collected from EORTC center records. Additionally, patients treated within the EORTC 62043 and 62072 trials were included in the analysis. Patient and tumor characteristics were documented. Response was assessed according to RECIST 1.1. and survival analysis was performed. Disease control rate was the total rate of: complete response, partial response and stable disease.

Results

Out of 52 patients, 40 (76.9%), 10 (19.2%) and 2 (3.8%) patients suffered from AS, HE, IS, respectively. Patient and tumor characteristics are illustrated in Table 1. The response rate was 8 (20%), 2 (20%) and 2 (100%) in the AS, HE and IS subtypes, respectively. Disease control rate was 37.5% and 60% in AS and HE, respectively. There was no difference in response rate of cutaneous AS and non-cutaneous AS (p = 0.86) and radiation-associated vs non-radiation-associated AS (p = 0.81). Median PFS and median OS (from commencing pazopanib) were 3 months (95% Cl: 2.1-4.4) and 9.9 months (95% Cl: 6.5-11.3) in AS, respectively.

Patient and tumor characteristics of vascular sarcomas

Angiosarcoma Hemangioendothelioma Intimal sarcoma
N = 40 N = 10 N = 2
N (%) N (%) N (%)
Median
age (years) 62.4 yrs 47.2 yrs 67.2 yrs
Gender
Female 15 (37.5%) 4 (40%) 1 (50%)
Male 20 (62.5%) 6 (60%) 1 (50%)
Disease stage
Locally advanced 8 (20%) 2 (20%) 1 (50%)
Metastatic 32 (80%) 8 (80%) 1 (50%)
Site of primary tumor
Breast 15 (37.5%) 0 (0%) 0 (0%)
Scalp/Head 6 (15%) 1 (10%) 0 (0%)
Abdomen 8 (20%) 4 (40%) 0 (0%)
Thorax 7 (17.5%) 4 (40%) 1 (50%)
Extremity 4 (10%) 1 (10%) 1(50%)
Localization
Skin 15 (37.5%) 0 (0%) 0 (0%)
Non-skin 24 (60%) 10 (100%) 2 (100%)
unknown 1 (2.5%) 0 (0%) 0 (0%)
Radiation-induced
Yes 14 (35%) 0 (0%) 0 (0%)
No 26 (65%) 10 (100%) 2 (100%)

Conclusions

Pazopanib demonstrated a degree of clinical efficacy in angiosarcoma, HE and IS. In AS patients, no difference in response rate was observed between cutaneous/ non-cutaneous and radiation-associated/ non radiation-associated tumors.

Clinical trial identification

Legal entity responsible for the study

EORTC Soft Tissue and Bone Sarcoma Group

Funding

EORTC

Disclosure

A. Kollar: Advisory Board for Novartis. S. Stacchiotti: Reserach funding: Glaxo and Novartis. W. van der Graaf: Research grants from Novartis and GSK. B. Kasper: Honoraria from Novartis. All other authors have declared no conflicts of interest.